Vyome Partners with a Large, Global Specialty Pharmaceutical Company to Market its Dandruff Products
NEW DELHI, India, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, today announces the licensing and supply if its novel products for the treatment of mild to moderate scalp seborrheic dermatitis, commonly known as dandruff, to its exclusive licensing and marketing partner in India. Vyome developed VB-001, an anti-dandruff lotion product, and VB-3222, an anti-dandruff shampoo using the company’s patented Molecular Replacement Therapeutics (MRT™) platform technology. Vyome has clinically tested these products with the demonstration of their clinical efficacy. Through its partnership with a global and large specialty pharmaceutical company, these products will be available through prescription marketing channel and chemists in India. Vyome retains the right to license and market these products in the rest of the world.
"Vyome is committed to developing innovative antimicrobial dermatological products to provide new treatment options for clinicians and patients,” said Venkateswarlu Nelabhotla (N. Venkat), co-founder and chief executive officer of Vyome Biosciences. “Dandruff affects approximately 50 percent of the world’s population including approximately 200 million patients in India. By partnering with a large specialty pharmaceutical company which is one of global leaders in dermatology, we will make our first two products available to patients with dandruff, for whom current therapeutic options are limited and often less effective.”
Vyome’s Molecular Replacement Therapeutics (MRTTM) are inspired by functional genomics to enhance the efficacy of antifungal agents. Leveraging its innovative antimicrobial technology platforms, Vyome is developing other novel products including VB 1953, a topical product candidate for moderate to severe acne, currently being initiated for Phase 2b clinical trials in the United States.
VB-001 is a clinically tested scalp care leave-on product designed for the treatment of mild seborrheic dermatitis, or dandruff. VB-001 uses Vyome’s patented Molecular Replacement Therapeutics (MRTTM) platform to outperform current gold standards in treatments of skin fungal infections, providing a potential solution for individuals with dandruff.
VB-3222 is a clinically tested anti-dandruff wash-off shampoo designed for the treatment of dandruff. Developed using Vyome’s MRTTM platform, VB-3222 is clinically proven to reduce scalp flaking and itching.
About Vyome Biosciences
Vyome Biosciences is an innovation-driven, clinical stage bio-pharmaceutical company, which has novel platform technologies and a deep pipeline of novel drugs for antibiotic resistant acne, and other opportunistic skin pathogens. The company’s lead drug candidate, VB 1953, is a topical treatment candidate for moderate and severe acne, has been clinically tested in Phase 1 in the United States and in a proof of concept efficacy study with successful outcomes, and is currently being studied in a Phase 2b study in the United States. Vyome has a deep pipeline of preclinical chemical entities, which are unique in their ability to overcome the development of resistance, and are based on its patented Dual Action Rational Therapeutics (DARTs) technology. Vyome has developed clinically proven antifungal products based on the innovative and patented Molecular Replacement Therapeutics (MRT™) technology platform. Vyome has assembled a world-class team of scientific and business development experts from India and the United States who have a track record of conducting scientific research, developing breakthrough products and building sustainable businesses. More information is available at www.vyome.in and @VyomeBio.
Josephine Belluardo, Ph.D.
LifeSci Public Relations
Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.